Skip to main content
Premium Trial:

Request an Annual Quote

Transgenomic Shares Down 11 Percent; Nasdaq Warning Imminent

NEW YORK, March 28 (GenomeWeb News) - Shares in Transgenomic were down 11.11 percent, or $.07, at $.56 in early-afternoon trading --- a few cents above their 52-week low --- prompting the likelihood that the company may get a delisting warning letter from the Nasdaq exchange on Wednesday.

 

If the stock fails to climb to above $1 by the close of market on Wednesday, it will mark 30 consecutive trading days that the shares have closed below $1. IN this case, Transgenomic will receive a warning letter from the Nasdaq threatening the firm with being delisted from the exchange.

 

Transgenomic's shares last closed above $1 on Feb. 14 when they closed at $1.04.

 

The Nasdaq exchange typically sends its listed companies such letters if their shares close below $1 for 30 consecutive trading days. The warning gives the company 90 days to return its closing share price to above $1. If the company fails to raise the price above $1 within 90 days after receiving the letter, and fails to maintain a closing price above that threshold for 10 trading days, it will be downgraded to the Nasdaq small-capitalization market.

 

A Transgenomic official did not immediately return a telephone call seeking comment.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.